JNJ-79635322

JNJ-79635322 is Johnson & Johnson's first trispecific antibody for multiple myeloma, binding BCMA and GPRC5D on myeloma cells plus CD3 on T cells in one molecule. J&J already sells teclistamab (BCMA x CD3) and talquetamab (GPRC5D x CD3); this candidate folds both targeting arms into one drug to address the BCMA-loss escape pattern seen after teclistamab failure. Initial Phase 1 data presented at ASCO 2025 showed an 86.1% ORR at the recommended Phase 2 dose (RP2D) and a 100% ORR in BCMA/GPRC5D-naive patients (n=27), with a 95% 12-month PFS in that subgroup [10]. A Phase 3 head-to-head versus an anti-BCMAxCD3 bispecific is now enrolling [1].

Novel compound, never approved anywhere. The clinical program is entirely J&J-sponsored and spans five trials. Phase 1 monotherapy in relapsed/refractory multiple myeloma and AL amyloidosis (NCT05652335, n=180, recruiting) [2]. Phase 1 combination with daratumumab plus or minus lenalidomide or pomalidomide (NCT06768489, n=140, recruiting) [3]. Phase 2 monotherapy with Overall Response Rate as the primary endpoint (NCT07266441, n=157) [4]. Phase 3 randomized comparison versus an anti-BCMAxCD3 bispecific (NCT07258511, n=400, recruiting) [1]. MajesTEC-5 (NCT05695508) is also J&J-sponsored (Janssen-Cilag) and tests teclistamab-based induction in transplant-eligible newly diagnosed MM - note this trial does not actually study JNJ-79635322; it is part of the broader MajesTEC franchise and is a J&J trial, not independent academic data [5]. No FDA breakthrough therapy, fast track, or orphan designations have been publicly disclosed for this specific compound, though J&J secured those designations for teclistamab and talquetamab in adjacent contexts. The Phase 3 trial only began recruiting recently; with 400 patients and ORR as the primary endpoint, a topline readout is unlikely before 2028. Watch ASH 2026 and 2027 for updated Phase 1/2 efficacy data that will set expectations going into the Phase 3 result. Enrollment totals across the J&J-sponsored JNJ-5322 trials approach 1,000 patients, which is aggressive for a Phase 1/2-stage asset and signals high internal conviction.

Multiple myeloma is a cancer of plasma cells, the antibody factories of the immune system. Two surface proteins are reliably expressed on those cells: BCMA (B-cell maturation antigen), a receptor that normal and malignant plasma cells use for survival signals, and GPRC5D, a poorly-understood G-protein coupled receptor whose expression is largely restricted to plasma cells and keratinized tissues like hair, nails, and tongue. Both targets are validated by approved drugs: teclistamab and elranatamab (BMS) pull T cells against BCMA, belantamab mafodotin delivers a cytotoxic payload to BCMA-expressing cells, and talquetamab pulls T cells against GPRC5D [6][7][11]. JNJ-79635322 fuses both T-cell engager strategies into one molecule. It has three binding arms: one grabs BCMA, one grabs GPRC5D, and one grabs CD3 (the activating receptor on T cells). Either tumor-binding arm can engage a myeloma cell, while the CD3 arm pulls in a T cell, forming a synapse that triggers killing. The clinical rationale: when teclistamab stops working, it is often because myeloma cells downregulate or lose BCMA expression entirely. A drug that can still bind through GPRC5D in those cells should rescue the response. Like every approved T-cell engager in MM, JNJ-79635322 requires step-up dosing to mitigate cytokine release syndrome - patients typically receive two to three priming doses with hospitalization before moving to full dose, then ongoing weekly or biweekly subcutaneous administration. That regimen is a real patient and infrastructure burden, and a key commercial differentiator when CAR-T offers a one-and-done alternative. The target biology is well-validated at the single-antigen level. The trispecific format itself is less proven. Several trispecific T-cell engagers have entered clinical trials across oncology, but none has reached approval. Manufacturing complexity, on-target toxicity stacking, and pharmacokinetic balancing across three binding arms remain real engineering challenges. The biology argues for this approach; the format adds execution risk on top.

The Phase 3 trial (NCT07258511) randomizes 400 patients with relapsed/refractory multiple myeloma to JNJ-79635322 versus an anti-BCMAxCD3 bispecific antibody, with ORR as the primary endpoint [1]. The comparator is unspecified in the registry; teclistamab is the most probable choice given J&J's franchise logic and trial-supply economics, but elranatamab (BMS) and linvoseltamab (Regeneron) cannot be ruled out. Confirmation of the comparator is a material unknown - a head-to-head against J&J's own teclistamab carries very different competitive and commercial implications than one against a rival's drug. ORR is a defensible primary endpoint in R/R MM because it correlates with PFS and OS in this setting and supports accelerated approval. Regulators have repeatedly accepted single-arm ORR for myeloma drugs targeting BCMA and GPRC5D. For a randomized Phase 3 against an active comparator, ORR delivers a faster readout than PFS but may not satisfy global payers without follow-on survival data. The Phase 2 trial (NCT07266441, n=157) is a single-arm ORR study that will likely generate the headline efficacy number before Phase 3 reads out [4]. The Phase 1 combination study (NCT06768489) testing JNJ-79635322 with daratumumab and IMiDs is positioning for earlier-line use [3]. AL amyloidosis is included as a Phase 1 expansion cohort in NCT05652335 - BCMA and GPRC5D are both expressed on the clonal plasma cells that drive AL amyloid deposition, so the mechanism translates, but the addressable population is small (~4,000 new US diagnoses/year) and likely represents a strategic option for orphan designation rather than a primary commercial driver. Total enrollment across the JNJ-5322 program is around 1,000 patients across four J&J-sponsored trials, an unusually aggressive footprint for a Phase 1/2-stage asset and a tell on internal prioritization.

Our model gives this drug a 52% chance of eventually being approved. That estimate starts from the historical approval rate for Phase 3 drugs in this area - about 57% - then adjusts based on ten facts about the trial and its sponsor. The number rises because of the trial's non-randomized design, its light or open-label blinding, and the sponsor's strong approval track record, and it falls because earlier-phase results were weak or limited. The remaining facts were close to average for this stage, so they left the estimate roughly where it started.

Efficacy risk is moderately de-risked by Phase 1 but not eliminated. Phase 1 ORR data are strong, but the BCMA-pretreated subgroup - the cleanest differentiation case - is still small. The Phase 3 design does not appear to enrich for BCMA-pretreated populations, which dilutes that case in the registrational readout. Safety risk is the central concern. Phase 1 reported 59% CRS (mostly Grade 1), but 28% Grade 3+ infections and four treatment-related deaths (including adenoviral encephalitis) is a meaningful signal [10]. Hypogammaglobulinemia from dual plasma-cell depletion (BCMA arm) appears to be additive with the immune dysfunction already seen with each single bispecific. GPRC5D engagement carries durable taste loss, skin rashes, and nail dystrophy in a large fraction of talquetamab patients [7]. The step-up dosing and weekly/biweekly subcutaneous administration schedule is also a real burden - patients need ongoing IVIG support and close infection monitoring. Competitive risk in R/R MM is severe. The patient pool is contested by: (1) two CAR-T products - ciltacabtagene autoleucel (cilta-cel, J&J/Legend) showed median PFS of ~34 months in CARTITUDE-4 in 1-3 prior lines, and idecabtagene vicleucel (ide-cel, BMS), both of which offer one-time dosing as the key differentiator versus chronic T-cell engager administration; (2) four approved bispecifics (teclistamab, talquetamab, elranatamab, linvoseltamab); (3) belantamab mafodotin, re-approved in 2023 in combination regimens after DREAMM-7/DREAMM-8 showed PFS benefit [11]; and (4) several other trispecifics in early development. Enrollment competition is brutal and commercial uptake will be a fight against drugs with established prescriber familiarity. Execution risk is moderate. J&J runs MM trials well, but the trispecific format adds manufacturing complexity (yield, aggregation, purity) that has historically tripped up multi-specific programs. Commercial risk: payers will scrutinize a trispecific priced above existing bispecifics in a class where teclistamab and talquetamab already sell. J&J has to justify a premium against its own drugs, and the franchise cannibalization story has to be net-positive on revenue.

Worth watching, and the Phase 1 readout at ASCO 2025 made it materially more interesting. The 100% ORR in BCMA/GPRC5D-naive patients and 70.4% CR rate are best-in-class numbers in R/R MM at the doses tested; if those hold in the Phase 2 (NCT07266441) and Phase 3, this becomes the new backbone for the J&J MM franchise. The safety signal - 28% Grade 3+ infections and four treatment-related deaths in Phase 1 - is the other side of that coin and is the data point most likely to constrain commercial uptake even if efficacy holds. The strategic context matters: J&J's new Medicine segment generated $57B of the company's ~$88.8B 2024 revenue [9], and oncology is the growth engine within it. J&J can afford to run a Phase 3 against (likely) its own teclistamab because the MM market is large enough to support multiple wins, and a working trispecific could become the next backbone for combination regimens. If this drug works, expect rapid push into earlier lines via the daratumumab and IMiD combination trial (NCT06768489). If you are tracking the broader T-cell engager class, this is the program to watch. It is the cleanest live test of whether multi-antigen targeting becomes a real platform or remains a one-product novelty. Catalysts: updated Phase 1/2 data at ASH 2026 (efficacy durability and infection-mitigation strategies), the Phase 2 ORR readout in 2027, and the Phase 3 topline in 2028.